Open AccessThis article is
- freely available
An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells
Department of Pharmacology, University of Minnesota, 210 Delaware Street Southeast Minneapolis, MN 55455, USA
Department of Therapeutic Radiology-Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Masonic Cancer Center, 425 East River Parkway Minneapolis, MN 55455, USA
* Author to whom correspondence should be addressed.
Received: 6 December 2012; in revised form: 19 January 2013 / Accepted: 22 January 2013 / Published: 28 January 2013
Abstract: Targeting and killing specific cells discriminately has been the goal of targeted therapy dating back to the era of Paul Ehrlich. The discovery of cancer stem cells has caused a paradigm shift within the cancer field and provided an opportunity to use targeted therapies such as targeted toxins to bind and kill these cells selectively. A number of targeted toxins have been developed against recently identified cancer stem cell markers. In this review we discuss the development and current status of these exciting novel drugs and their potential use to combat drug-refractory relapse.
Keywords: cancer stem cells; targeted toxins; immunotoxins; CD133; EpCAM; CD123; CD44
Citations to this Article
Cite This Article
MDPI and ACS Style
Waldron, N.N.; Vallera, D.A. An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies 2013, 2, 82-92.
Waldron NN, Vallera DA. An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells. Antibodies. 2013; 2(1):82-92.
Waldron, Nate N.; Vallera, Daniel A. 2013. "An Old Idea Tackling a New Problem: Targeted Toxins Specific for Cancer Stem Cells." Antibodies 2, no. 1: 82-92.